Understanding Intracranial Hypertension
Intracranial hypertension (IH) refers to elevated pressure inside the skull. When no tumor, bleeding, or infection is present, it is often termed Idiopathic Intracranial Hypertension (IIH)—also known as pseudotumor cerebri. IIH most commonly affects young women but can occur in all age groups.
Common Symptoms of Intracranial Hypertension
Patients typically experience:
- Persistent headache
- Pulsatile tinnitus (whooshing sound in the ears)
- Blurred or double vision
- Papilledema (optic nerve swelling)
- Progressive vision loss
If untreated, intracranial hypertension can cause permanent visual impairment due to optic nerve damage. Early diagnosis and targeted treatment are critical.
Why Does Intracranial Pressure Rise?
Emerging research has demonstrated that many patients with IIH have venous outflow obstruction, particularly narrowing (stenosis) of the transverse or sigmoid dural venous sinuses. These sinuses drain blood from the brain. When narrowed, venous pressure rises, impairing cerebrospinal fluid (CSF) absorption and increasing intracranial pressure.
Diagnostic Imaging and Hemodynamic Evaluation
- Magnetic Resonance Venography (MRV) often reveals bilateral transverse sinus stenosis in a large proportion of IIH patients.
- Manometry during venography confirms a measurable pressure gradient across the stenosis.
This understanding has paved the way for a targeted endovascular solution: dural venous sinus stenting.
What Is Dural Venous Sinus Stenting?
Dural sinus stenting is a minimally invasive endovascular procedure performed by a neurointerventional specialist.
Step-by-Step Procedure
Through a small puncture (typically femoral or radial access):
- A catheter is advanced into the venous sinuses.
- Pressure measurements are obtained across the stenosis.
- A self-expanding stent is deployed to open the narrowed sinus.
- Venous outflow is restored, reducing intracranial venous pressure.
Unlike shunt surgery, which diverts CSF, venous sinus stenting addresses the underlying venous obstruction.
Scientific Evidence Supporting Venous Sinus Stenting
Over the past decade, multiple prospective series and multicenter studies have demonstrated strong efficacy and safety.
Reported Clinical Outcomes
Large observational cohorts report:
- Headache improvement in 70–90% of patients
- Papilledema resolution in over 80%
- Significant improvement in visual fields
- Durable pressure gradient elimination
A systematic review involving over 1,000 treated patients showed:
- High technical success rates (>95%)
- Low major complication rates (typically 2–4%)
The Venous Sinus Stenting for Idiopathic Intracranial Hypertension Registry and multicenter prospective data have reinforced:
- Sustained symptom relief at 1–3 years follow-up
- Low restenosis rates (generally <10%)
- Reduced need for CSF shunting procedures
Importantly, pressure gradients of ≥8–10 mmHg across stenosis are commonly used as hemodynamic criteria for stenting candidacy.
How Does Venous Sinus Stenting Compare to Traditional Treatments?
Standard Treatments for Intracranial Hypertension
- Weight reduction
- Acetazolamide therapy
- Lumbar puncture
- Optic nerve sheath fenestration
- CSF shunting
While effective in some cases, shunting carries risks of infection, obstruction, over-drainage, and frequent revisions.
Advantages of Venous Sinus Stenting
- Targeted correction of venous pathology
- Lower revision rates compared with shunts
- Immediate pressure gradient resolution
- Rapid symptomatic improvement
Who Is a Candidate for Dural Sinus Stenting?
Dural sinus stenting is considered in patients with:
- Documented intracranial hypertension
- Papilledema or vision decline
- Transverse sinus stenosis on MRV
- Measurable pressure gradient on venous manometry
- Failure of maximal medical therapy
Careful multidisciplinary evaluation—including neuro-ophthalmology and neurointervention—is essential.
Safety Profile of Venous Sinus Stenting
Complication rates are relatively low in experienced centers. Reported risks include:
- Venous perforation (rare)
- In-stent thrombosis (minimized with antiplatelet therapy)
- Restenosis
With modern technique and careful patient selection, major complication rates are generally below 5%.
The Future of Intracranial Hypertension Treatment
Ongoing research is focusing on:
- Refining patient selection criteria
- Long-term durability beyond five years
- Optimal antiplatelet regimens
- Advanced venous flow imaging
As understanding of venous physiology improves, venous sinus stenting is becoming an increasingly accepted standard for medically refractory IIH.
Key Takeaway
Intracranial hypertension, particularly Idiopathic Intracranial Hypertension (IIH), can threaten vision and quality of life. Dural venous sinus stenting represents a scientifically supported, minimally invasive endovascular therapy that directly addresses venous outflow obstruction.
In properly selected patients, stenting provides high rates of headache relief, papilledema resolution, and visual stabilization with durable long-term outcomes.
Modern neurointerventional techniques are transforming the management of intracranial hypertension—from symptomatic management to precision vascular correction—offering hope, safety, and lasting results.
The Stroke Center is a specialized neurovascular facility dedicated to advanced stroke care and minimally invasive endovascular treatments under the leadership of Dr. Nishant Aditya, an experienced Consultant Interventional Neuroradiologist with extensive expertise in mechanical thrombectomy, aneurysm coiling, carotid and intracranial stenting, and complex brain vascular interventions. With advanced training including fellowship experience at , Dr. Nishant Aditya combines state-of-the-art imaging technology, evidence-based protocols, and precision-driven endovascular techniques to provide rapid diagnosis, timely stroke intervention, and comprehensive long-term neurovascular care focused on improving survival, reducing disability, and enhancing patient outcomes.